Feed XCUR
XC

Exicure, Inc.

XCUR · NASDAQ

$1.25 +0.56% (+$0.01)
1M +6.96%
Market Cap $8.60M
P/E Ratio -
Div. Yield -
ROE 237.91%
Piotroski F-Score Weak
1/9
Valuation
0 /100
Expensive
P/B 8.81x
P/FCF N/A
P/S N/A
Growth
0 /100
Declining
Book val. growth 35.92%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor
Asset turnover 0.00x
ROA 72.69%
ROIC 93.88%
Debt
48 /100
Moderate
Current ratio 0.56x
Int. coverage -8,917.00x
Debt/Equity 0.00x
Stability
1 /100
Unstable
EPS volatility 181.89%
Profitable years 0
Beta 3.62x

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about XCUR
Online

About the company

Exicure, Inc. is a biopharmaceutical company focused on developing novel therapeutics based on the technology of therapeutic coding. Its main product platform is based on a technology called Spherical Nucleic Acid (SNA™), which enables the creation of three-dimensional structures of nucleic acids that have the potential to modulate gene expression. Exicure aims to utilize this technology to develop therapeutics for various indications, including oncological diseases, dermatological conditions, and neurological disorders. The company also engages in research and development of therapeutic vaccines based on SNA™ technology. Exicure collaborates with pharmaceutical companies and academic institutions on the development and commercialization of its products. Shares of Exicure, Inc. may be an interesting investment opportunity for investors following the pharmaceutical industry and biopharmaceutical research.

Sector

Healthcare

Industry

Biotechnology

CEO

Jungsoo Kim

Employees

1

Headquarters

Redwood City

Upcoming events

12 NOV

Earnings

Upcoming earnings report

53d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.